Six biotech companies completed initial public offerings in the first quarter of 2026, maintaining the sector's historically slow IPO pace while achieving significantly larger fundraising rounds. The companies raised a median of $287.5 million, according to BioPharma Dive data, a figure that far exceeds what has been observed in similar timeframes in previous years.
The data suggests biotech companies are waiting longer to go public but commanding higher valuations when they do reach the market. This trend reflects investors' increasing selectivity in the biotech sector, favoring companies with more mature pipelines and clearer paths to commercialization.